



PROFESSOR MARK W J FERGUSON

Professor Mark Ferguson is the Co-founder (with Dr Sharon O’Kane) and CEO of Renovo a Biotechnology Company spun out of the University of Manchester, which is developing novel pharmaceutical therapies to prevent scarring or accelerate healing following wounding (www.renovo.com). Following two rounds of private venture capital funding (totalling £32M) Renovo successfully completed an IPO on the Main list of the London Stock Exchange in April 2006, raising £67.5M. Renovo partnered its lead drug, Juvista for scar reduction, with Shire in a \$825M plus royalties deal retaining all EU rights, where it intends to commercialise itself. Renovo has three drugs in the clinic: Juvista in PhIII, with 8 clinically and statistically significant PII efficacy trials, Juvindex, Adaprev and Prevascar in PII, and over a dozen preclinical candidates. Since the age of 28, Mark Ferguson has been Professor in the School of Biological Sciences at the University of Manchester, where he has held a number of administrative posts including Head of Department and Dean. He is the recipient of numerous international awards, prizes and honours for this research work, including the 2002 European Science Prize, and is the author of over 400 research papers, books and patents

Mark Ferguson graduated from the Queens University of Belfast with degrees in Dentistry (BDS), Anatomy and Embryology (BSc, PhD) and Medical Sciences (DMedSc), holds Fellowships from the Royal Colleges of Surgeons in Ireland (FFD) and Edinburgh (FDS) and is a Founding Fellow of the UK Academy of Medical Sciences (FMed Sci). He is a Member or Fellow of a number of learned Societies, Past President and Secretary of the European Tissue Repair Society and was made a “Commander of the British Empire” (CBE) by the Queen in 1999 for services to Health and Life Sciences.

<http://www.termis.org/eu2010/keynote.php>